Chinese AI lab automation firm MegaRobo raises nearly $200 million from Oman’s sovereign wealth fund and global investors.
A Chinese technology company that uses robots and smart computers to help discover new medicines has raised nearly $200 million in fresh funding to expand its business around the globe.
Announced on November 19, 2026, from Suzhou and Beijing in China, the funding round for MegaRobo Technologies includes major backing from the Oman Investment Authority, which is the national wealth fund of the Middle Eastern nation of Oman, alongside Chinese investment firm CMB International and returning supporters Asia Investment Capital, Granite Asia, and Sinovation Ventures.
MegaRobo plans to use this new cash to build even smarter laboratory robots and bring its automated research systems to drug makers across the Middle East, Europe, North America, and Asia.
For decades, inventing a new medicine has been a slow, expensive, and tiring process. Human scientists spend years mixing tiny drops of chemicals by hand, testing thousands of ingredients one by one, and waiting months just to see if a new treatment works.
While early AI programs could read medical books and suggest ideas on a computer screen, they still needed people to run the tests in a real science lab.
MegaRobo solves this problem by connecting a smart computer brain directly to hardworking robotic arms inside modern laboratories.
Its system designs a medical experiment, instructs the robots to mix the chemicals and run the test, watches the results through sensors, and immediately learns what to try next.
By letting robots work around the clock without getting tired or making human mistakes, pharmaceutical companies can find promising new treatments much faster and at a much lower cost.
“The first generation of AI learned from humanity’s accumulated knowledge. The next generation will increasingly learn by acting in the physical world, through experiments, production and continuous feedback,” said Daniel Huang, Founder and Chief Executive Officer of MegaRobo.
“That shift changes AI from a system that interprets the world into one that can help create new knowledge, materials, processes and products. MegaRobo is building the infrastructure for that transition.”
Founded in 2016, MegaRobo has already supplied its robotic lab systems to more than 500 pharmaceutical companies, biotechnology firms, and university research centers.
While roughly eighty percent of its business currently comes from inside China, the company is preparing to sell shares on the Hong Kong stock market and sees huge opportunities to grow overseas, especially in countries connected through regional trade partnerships.
See Also: Lenovo Sales Surge to $30.2 Billion as Businesses Rush to Buy AI Computer Equipment
The investment from Oman’s national wealth fund also highlights deepening business ties between China and the Middle East, following multibillion-dollar cooperation agreements signed between the two nations earlier this month.
Long-term investors say MegaRobo stands out because it successfully combines smart software with physical factory and laboratory machines that real companies actually buy and use every day.
“As a long-term shareholder, we have seen MegaRobo continuously drive innovation, earn the trust of its customers and translate its technological capabilities into commercial applications,” said Liu Erh Fei, Founding Partner and Chief Executive Officer of Asia Investment Capital.
“Its ability to integrate AI, software and hardware, together with its experience in scientific research and advanced manufacturing, underpins our continued investment.”
With total funding now reaching roughly $600 million, MegaRobo is opening up its automated laboratories to scientists worldwide so researchers can test thousands of new protein designs against real-world lab results.
For everyday patients and families, faster robotic drug discovery means lifesaving medicines and better treatments could reach hospitals and local pharmacies years sooner than before.

